AH

Arne Handeland

Board Member at JSB Group

📍 Oslo, Oslo, Norway🔄 Updated October 2026💼 14 investments📅 23 years investing🗓 Last invested Jun 2017
VC🌍 Norway
14
Total investments
0
Early stage
0
Mid stage
0
Late stage
23y
Years active

Portfolio

4 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board member
Jan 2011
Technology Ecocat catalytic washcoat concepts – Tailored to your needs Washcoat charasteristics play a major role in catalytic converter conversion efficiency and durability against aging. By modifying the washcoat, catalyst selectivity and performance can be adjusted based on customer requirements, raw emissions and fuel quality. This enables maximum conversions with minimum catalyst volume and use of precious metals. The functioning of catalytic coatings is based on precious metals´ (Platinum, Palladium and Rhodium) reactions with emissions components in exhaust gas. As an outcome, carbon monoxide CO and hydrocarbons HC oxidise into CO2 and water while reducing NOx to nitrogen. Besides 3-way, diesel oxidation, diesel filtration, urea hydrolysis, SCR, CNG and bi-fuel concepts, Ecocat has developed its coating solutions for different volatile organic compounds (VOCs). Ecocat substrate technologies – Multiple choices for multiple applications Ecocat's substrate selection includes conventional straight-channel, turbulence, mixer and partial filter types. Substrates are designed and manufactured in different sizes, shapes and cell densities from two wheelers to cars and heavy-duty applications as well as solutions for large stationary engines. Ecocat´s metallic matrix substrates offer superior properties in back pressure, weight, packaging size/shape flexibility and low volume advantage. With metallic substrates it has been possible to utilize inter-channel communication in order to equalize flow and heat distribution, improve mass and heat transfer and trap diesel particulates.
Board member
Jun 2004
About Affitech A/S was formed in May 2009 by a combination of Oslo, Norway-based Affitech AS, a human antibody therapeutics research company and Pharmexai A/S, a publicly traded former vaccine research and development company, based in Denmark. The combination starts the transformation of Affitech into a major human antibody company with research labs in Oslo, Norway and Finance, Administration, Investor Relations and Communications in Copenhagen, Denmark.
Experience · 15 entries
All (15)
Investments (14)
Board (14)
2017
2016
JSB Group AS
Member of the Board
May 2016
Jupiter AS
Member of the Board
May 2016
IV Group AS
Board Member
May 2016
JupiterBach AS
Board Member
May 2016
Show all 15 entries ↓
Investment activity
2003–2017 · 14 investments
200322004120061200712010220111201212016420171
Recent (last 2 years)Earlier